These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2906876)

  • 1. Safety and pharmacokinetics of mifentidine after increasing oral doses in healthy subjects.
    Imbimbo BP; Seiberling M; Peuckert U; Hoexter G; Maier-Lenz H; Vidi A; Daniotti S
    Eur J Clin Pharmacol; 1988; 35(6):673-6. PubMed ID: 2906876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of mifentidine after single and multiple oral administration to healthy volunteers.
    Imbimbo BP; Urso R; Thieme G; Sturn B; Ueckert B; Vidi A; Ladinsky H; Daniotti S
    Br J Clin Pharmacol; 1988 Oct; 26(4):407-13. PubMed ID: 2903762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of mifentidine, a new H2-antagonist, on pentagastrin-stimulated acid secretion in healthy subjects.
    Lazzaroni M; Ardizzone S; Imbimbo BP; Sangaletti O; Ghirardosi C; Bianchi Porro G
    Int J Clin Pharmacol Ther Toxicol; 1987 Apr; 25(4):218-21. PubMed ID: 2884190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastric acid and pepsin secretion after single oral doses of mifentidine in healthy subjects.
    Lazzaroni M; Imbimbo BP; Sangaletti O; Bianchi Porro G
    Scand J Gastroenterol; 1988 Sep; 23(7):788-92. PubMed ID: 2906453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the new H2-receptor antagonist mifentidine on gastric acid secretion in the cat: comparison with cimetidine and ranitidine.
    Scarpignato C; Tramacere R; Tangwa M; Bertaccini G
    Arch Int Pharmacodyn Ther; 1985 Jul; 276(1):142-51. PubMed ID: 2864903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo-in vitro correlations with a commercial dissolution simulator. Studies on the H2 receptor antagonist mifentidine.
    Erol DD; Rosen A
    Arzneimittelforschung; 1996 Oct; 46(10):986-9. PubMed ID: 8931893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the new H2-receptor antagonist mifentidine on gastric secretion, gastric emptying and experimental gastric and duodenal ulcers in the rat: comparison with cimetidine and ranitidine.
    Scarpignato C; Tangwa M; Tramacere R; Del Soldato P
    Digestion; 1986; 33(1):7-16. PubMed ID: 2866139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mifentidine: evaluation of antiandrogen effects and kidney function studies.
    Francalanza G; Franco C; Giachetti A
    Arzneimittelforschung; 1985; 35(1A):456-8. PubMed ID: 2859037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Action of mifentidine on the secretory response to sham feeding and pentagastrin and on serum gastrin in duodenal ulcer patients.
    Bianchi Porro G; Lazzaroni M; Imbimbo BP; Sangaletti O; Ghirardosi C; Daniotti S
    Eur J Clin Pharmacol; 1987; 32(6):555-8. PubMed ID: 2888658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.
    Lin JH
    Clin Pharmacokinet; 1991 Mar; 20(3):218-36. PubMed ID: 1673880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of oxmetidine, a new histamine H2-receptor antagonist, after single oral and intravenous doses.
    Jönsson KA; Bodemar G; Gotthard R; Norlander B; Walan A
    Eur J Clin Pharmacol; 1983; 24(3):353-6. PubMed ID: 6134622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
    Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
    Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study of mifentidine and ranitidine in the short-term treatment of duodenal ulcer.
    Sabbatini F; Lazzaroni M; Petrillo M; Piai G; Mazzacca G; Bianchi Porro G
    Eur J Clin Pharmacol; 1990; 39(5):515-7. PubMed ID: 1981748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etintidine-theophylline interaction study in humans.
    Huang SM; Weintraub HS; Marriott TB; Marinan B; Abels R; Leese PT
    Biopharm Drug Dispos; 1987; 8(6):561-9. PubMed ID: 2892545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
    van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
    Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacodynamics and pharmacokinetics of multiple doses of the new H2-receptor antagonist, roxatidine acetate, in healthy men.
    Lassman HB; Ho I; Puri SK; Sabo R; Scheffler MR
    Drugs; 1988; 35 Suppl 3():53-64. PubMed ID: 2905250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of CM 57755, a new histamine H2-receptor antagonist, after single oral doses in man.
    Necciari J; Mery D; Garriot P; Escourrou J; Cautreels W
    Int J Clin Pharmacol Res; 1985; 5(6):457-65. PubMed ID: 2869002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.